Head and neck surgery during the coronavirus-19 pandemic: The University of California San Francisco experience.


Journal

Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541

Informations de publication

Date de publication:
02 2021
Historique:
received: 23 06 2020
revised: 02 10 2020
accepted: 13 10 2020
pubmed: 25 10 2020
medline: 20 1 2021
entrez: 24 10 2020
Statut: ppublish

Résumé

Guidelines regarding head and neck surgical care have evolved during the coronavirus-19 (COVID-19) pandemic. Data on operative management have been limited. We compared two cohorts of patients undergoing head and neck or reconstructive surgery between March 16, 2019 and April 16, 2019 (pre-COVID-19) and March 16, 2020 and April 16, 2020 (COVID-19) at an academic center. Perioperative, intraoperative, and postoperative outcomes were recorded. There were 63 operations during COVID-19 and 84 operations during pre-COVID-19. During COVID-19, a smaller proportion of patients had benign pathology (12% vs 20%, respectively) and underwent thyroid procedures (2% vs 23%) while a greater proportion of patients underwent microvascular reconstruction±ablation (24% vs 12%,). Operative times increased, especially among patients undergoing microvascular reconstruction±ablation (687 ± 112 vs 596 ± 91 minutes, P = .04). Complication rates and length of stay were similar. During COVID-19, perioperative outcomes were similar, operative time increased, and there were no recorded transmissions to staff or patients. Continued surgical management of head and neck cancer patients can be provided safely.

Sections du résumé

BACKGROUND
Guidelines regarding head and neck surgical care have evolved during the coronavirus-19 (COVID-19) pandemic. Data on operative management have been limited.
METHODS
We compared two cohorts of patients undergoing head and neck or reconstructive surgery between March 16, 2019 and April 16, 2019 (pre-COVID-19) and March 16, 2020 and April 16, 2020 (COVID-19) at an academic center. Perioperative, intraoperative, and postoperative outcomes were recorded.
RESULTS
There were 63 operations during COVID-19 and 84 operations during pre-COVID-19. During COVID-19, a smaller proportion of patients had benign pathology (12% vs 20%, respectively) and underwent thyroid procedures (2% vs 23%) while a greater proportion of patients underwent microvascular reconstruction±ablation (24% vs 12%,). Operative times increased, especially among patients undergoing microvascular reconstruction±ablation (687 ± 112 vs 596 ± 91 minutes, P = .04). Complication rates and length of stay were similar.
CONCLUSIONS
During COVID-19, perioperative outcomes were similar, operative time increased, and there were no recorded transmissions to staff or patients. Continued surgical management of head and neck cancer patients can be provided safely.

Identifiants

pubmed: 33098178
doi: 10.1002/hed.26514
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

622-629

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Johns Hopkins University. Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html. Accessed June 9, 2020.
American Cancer Society. Cancer Fact and Figures 2020. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2020.html. Accessed June 9, 2020.
Kutikov A, Weinberg DS, Edelman MJ, Horwitz EM, Uzzo RG, Fisher RI. A war on two fronts: cancer care in the time of COVID-19. Ann Intern Med. 2020;172(11):756-758.
Civantos FJ, Leibowitz JM, Arnold DJ, et al. Ethical surgical triage of patients with head and neck cancer during the COVID-19 pandemic. Head Neck. 2020;42(7):1423-1447.
MD Anderson Head and Neck Surgery Treatment Guidelines Consortium, Consortium members, Maniakas A, Jozaghi Y, et al. Head and neck surgical oncology in the time of a pandemic: subsite-specific triage guidelines during the COVID-19 pandemic. Head Neck. 2020;42(6):1194-1201.
Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783-791.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.
Jensen AR, Nellemann HM, Overgaard J. Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiother Oncol. 2007;84(1):5-10.
Park JS, El-Sayed IH, Young VN, Pletcher SD. Development of clinical care guidelines for faculty and residents in the era of COVID-19. Head Neck. 2020;42:1403-1408.
Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381.
Amin MB, Edge S, Greene F, et al., eds. AJCC Cancer Staging Manual. 8th Edition. New York: Springer; 2017.
Han AY, Miller JE, Long JL, St John MA. Time for a paradigm shift in head and neck cancer management during the COVID-19 pandemic. Otolaryngol Head Neck Surg. 2020;163(3):447-454.
Chaves ALF, Castro AF, Marta GN, et al. Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic. Oral Oncol. 2020;107:104734.
Topf MC, Shenson JA, Holsinger FC, et al. Framework for prioritizing head and neck surgery during the COVID-19 pandemic. Head Neck. 2020;42(6):1159-1167.
Fakhry N, Schultz P, Moriniere S, et al. French consensus on management of head and neck cancer surgery during COVID-19 pandemic. Eur Ann Otorhinolaryngol Head Neck Dis. 2020;137(3):159-160.
Kowalski LP, Sanabria A, Ridge JA, et al. COVID-19 pandemic: effects and evidence-based recommendations for otolaryngology and head and neck surgery practice. Head Neck. 2020;42(6):1259-1267.
Graboyes EM, Kompelli AR, Neskey DM, et al. Association of treatment delays with survival for patients with head and neck cancer: a systematic review. JAMA Otolaryngol Head Neck Surg. 2019;145(2):166-177.
Schutte HW, Heutink F, Wellenstein DJ, et al. Impact of time to diagnosis and treatment in head and neck cancer: a systematic review. Otolaryngol Head Neck Surg. 2020;162(4):446-457.
Brody RM, Albergotti WG, Shimunov D, Nicolli E, Harris BN, Bur AM. Changes in head and neck oncologic practice during the COVID-19 pandemic. Head Neck. 2020;42:1448-1453.
Heffernan DS, Evans HL, Huston JM, et al. Surgical infection society guidance for operative and peri-operative care of adult patients infected by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Surg Infect (Larchmt). 2020;21(4):301-308.
Amonkar MM, Chastek B, Samant N, Teitelbaum A. Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population. J Med Econ. 2011;14(4):421-432.
Dautremont JF, Rudmik LR, Nakoneshny SC, et al. Understanding the impact of a clinical care pathway for major head and neck cancer resection on postdischarge healthcare utilization. Head Neck. 2016;38(Suppl 1):E1216-E1220.
Silverman DA, Lin C, Tamaki A, et al. Respiratory and pulmonary complications in head and neck cancer patients: evidence-based review for the COVID-19 era. Head Neck. 2020;42(6):1218-1226.

Auteurs

Katherine C Wai (KC)

Department of Otolaryngology Head and Neck Surgery, University of California, San Francisco, California, USA.

Mary Jue Xu (MJ)

Department of Otolaryngology Head and Neck Surgery, University of California, San Francisco, California, USA.

Rex H Lee (RH)

School of Medicine, University of California, San Francisco, California, USA.

Ivan H El-Sayed (IH)

Department of Otolaryngology Head and Neck Surgery, University of California, San Francisco, California, USA.

Jonathan R George (JR)

Department of Otolaryngology Head and Neck Surgery, University of California, San Francisco, California, USA.

Chase M Heaton (CM)

Department of Otolaryngology Head and Neck Surgery, University of California, San Francisco, California, USA.

P Daniel Knott (PD)

Department of Otolaryngology Head and Neck Surgery, University of California, San Francisco, California, USA.

Andrea M Park (AM)

Department of Otolaryngology Head and Neck Surgery, University of California, San Francisco, California, USA.

William R Ryan (WR)

Department of Otolaryngology Head and Neck Surgery, University of California, San Francisco, California, USA.

Rahul Seth (R)

Department of Otolaryngology Head and Neck Surgery, University of California, San Francisco, California, USA.

Patrick K Ha (PK)

Department of Otolaryngology Head and Neck Surgery, University of California, San Francisco, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH